The current landscape presents an urgent unmet need—no clinically approved inhibitors specifically targeting PAR-2 have successfully translated into CRC management strategies, leaving patients without targeted interventions against this key inflammatory mediator. Here, F2RL1 is linked to colorectal carcinoma.